Ligand Reports First Quarter 2021 Financial Results
Search jobs
Conference Call Begins at 4:30 p.m. Eastern Time Today
SAN DIEGO (BUSINESS WIRE) $LGND#earnings
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
“This year has opened strong for Ligand with solid financial performance and great results from all of our core technology platforms,” said John Higgins, Chief Executive Officer. “We are very pleased to report a smooth and efficient integration of the four acquisitions we closed last year. Our R&D team has expanded considerably and we are reaping the benefits of these transactions with more licensing deals and contract revenue. Working within a highly dynamic and unpredictable COVID-19 landscape, we
Published April 28, 2021 at 9:21 AM MDT Listen • 5:05
/ A new report from Utah housing advocates shows the state could lose 40% of federally subsidized rentals for older adults by 2045. This story and more in the Wednesday morning news brief.
Wednesday morning, April 28, 2021
State
A new report from Utah housing advocates shows the state could
lose 40% of federally subsidized rentals for older adults by 2045. Otelo Reggy-Beane with the Utah Housing Coalition authored the report. He said subsidized units are being converted into market-rate spaces, and that forcing seniors to relocate can “negatively impact their physical and mental health and increase their likelihood of experiencing homelessness.” Reggy-Beane said many older people rely on fixed incomes, and with current housing prices, that’s not enough to afford market-rate rent. He recommended that state and local governments dedicate funds to preserving senior housing.
Read Time: 4 minutes
Mary Beckerle, PhD
The National Academy of Sciences has elected Mary Beckerle, PhD, Huntsman Cancer Institute (HCI) CEO and distinguished professor of biology and oncological sciences at the University of Utah (U of U), as a member. Beckerle is among 120 newly elected members announced in a press release during the annual meeting of the National Academy of Sciences.
Election as a member in this organization is widely accepted as a mark of excellence in scientific achievement and is considered one of the highest honors a scientist can receive. Of its more than 2,400 current members, approximately 190 have received a Nobel Prize, according to the National Academy of Sciences.
Credit: Huntsman Cancer Institute
SALT LAKE CITY - The National Academy of Sciences has elected Mary Beckerle, PhD, Huntsman Cancer Institute (HCI) CEO and distinguished professor of biology and oncological sciences at the University of Utah (U of U), as a member. Beckerle is among 120 newly elected members announced in a press release during the annual meeting of the National Academy of Sciences.
Election as a member in this organization is widely accepted as a mark of excellence in scientific achievement and is considered one of the highest honors a scientist can receive. Of its more than 2,400 current members, approximately 190 have received a Nobel Prize, according to the National Academy of Sciences.
Canva; Everyday Health
The annual meeting of the American Association for Cancer Research (AACR) is one of the largest cancer research meetings of its kind, bringing together a range of researchers, from those who spend their time in the lab to those who focus on patients in the clinic. The meeting atmosphere is electric even when it’s virtual. Here are five key studies that stood out during the first week of the virtual AACR meeting, held April 10–15, 2021.
Lymphoma Progression Cut in Half When Rituxan Is Paired With Aliqopa
What’s new Patients with relapsed indolent non-Hodgkin lymphoma saw a 48 percent reduced risk of progression (time without the disease advancing or death) when the targeted therapy Aliqopa (copanlisib) was used in combination with Rituxan (rituximab) versus Rituxan alone. Rituxan alone is the current standard therapy for relapses. The results, which come from a phase 3 trial known as CHRONOS-3, were announced at the AACR meeting and simultaneously p